Skip to main content
Canna~Fangled Abstracts

Cannabidiol Suppresses Metastatic Castration-Resistant Prostate Cancer Progression and Recurrence through Modulating Tryptophan Catabolism

By December 19, 2024No Comments

. 2024 Oct 17;7(12):3902-3913.

doi: 10.1021/acsptsci.4c00448. eCollection 2024 Dec 13.

Ethar A Mudhish 1, Hassan Y Ebrahim 1, Iman E Helal 1 2, Abdullah T Alhowiriny 1, Khalid A El Sayed 1
Affiliations 

Abstract

Metastatic castration-resistant prostate cancer (mCRPC) is an aggressive phenotype of prostate cancer (PC). Tryptophan oxidative catabolism by indoleamine 2,3-dioxygenase-1 (IDO1) cleaves the indole ring to kynurenine (Kyn), an endogenous ligand for the aryl hydrocarbon receptor (AhR), which activates multiple tumorigenesis pathways. The IDO1-Kyn-AhR axis is aberrantly dysregulated in mCRPC. (-)-Cannabidiol (CBD) is a nonpsychoactive phytocannabinoid. CBD showed antitumor activities against human malignancies, including PC. CBD showed potent in vitro dose-dependent reduction of viability and clonogenicity of diverse human PC cell lines. CBD reduced the expression of IDO1 and AhR in PC cells. A daily 15 mg/kg oral dose of CBD for 30 days effectively suppressed the progression of the mCRPC CWR-R1ca-Luc cells xenografted in male nude mice. Continued CBD oral dosing for an additional 45 days suppressed the CWR-R1ca-Luc tumor locoregional and distant recurrences after the primary tumors’ surgical excision. Collected CBD-treated tumors showed a reduced level of IDO1 expression. CBD-treated mice displayed a significant systemic reduction of Kyn. CBD is a novel, nonpsychoactive phytocannabinoid lead useful for the control of mCRPC via targeting the tryptophan catabolism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

References

    1. Sung H.; Ferlay J.; Siegel R. L.; Laversanne M.; Soerjomataram I.; Jemal A.; Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin 2021, 71, 209–249. 10.3322/caac.21660. – DOI – PubMed
    1. Siegel R.; Giaquinto A. N.; Jemal A. Cancer Statistics, 2024. CA Cancer J. Clin. 2024, 74, 12–49. 10.3322/caac.21820. – DOI – PubMed
    1. Giri V. N.; Morgan T. M.; Morris D. S.; Berchuck J. E.; Hyatt C.; Taplin M. E. Genetic testing in prostate cancer management: Considerations informing primary care. CA Cancer J. Clin 2022, 72, 360–371. 10.3322/caac.21720. – DOI – PubMed
    1. Bishop J. L.; Thaper D.; Vahid S.; Davies A.; Ketola K.; Kuruma H.; Jama R.; Nip K. M.; Angeles A.; Johnson F.; Wyatt A. W. The master neural transcription factor BRN2 Is an androgen receptor–suppressed driver of neuroendocrine differentiation in prostate cancer BRN2 is an AR-suppressed driver of NEPC. Cancer Discov. 2017, 7, 54–71. 10.1158/2159-8290.CD-15-1263. – DOI – PubMed
    1. Opitz C. A.; Patterson L. F. S.; Mohapatra S. R.; Dewi D. L.; Sadik A.; Platten M.; Trump S. The therapeutic potential of targeting tryptophan catabolism in cancer. Br. J. Cancer 2020, 122, 30–44. 10.1038/s41416-019-0664-6. – DOI – PMC – PubMed

Leave a Reply